{"id":22593,"date":"2024-03-27T10:29:55","date_gmt":"2024-03-27T09:29:55","guid":{"rendered":"https:\/\/mabdesign.fr\/atonco-nouvea-membre\/"},"modified":"2024-03-27T10:47:14","modified_gmt":"2024-03-27T09:47:14","slug":"atonco-nouvea-membre","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/","title":{"rendered":"Atonco – new member"},"content":{"rendered":"\n

Atonco est une soci\u00e9t\u00e9 radiopharmaceutique au stade clinique qui d\u00e9veloppe des produits radiopharmaceutiques innovants utilisant l\u2019astate-211, un radionucl\u00e9ide \u00e9metteur de particules alpha pour le traitement du cancer. Atonco, fond\u00e9e en 2019 et construite avec une \u00e9quipe exp\u00e9riment\u00e9e et passionn\u00e9e, poss\u00e8de des licences mondiales exclusives pour l\u2019utilisation d\u2019un anticorps et d\u2019une technologie propri\u00e9taire de radiomarquage innovante.<\/p>\n\n\n\n

Atonco, bas\u00e9e sur une alpha-immunoth\u00e9rapie disruptive et innovante, r\u00e9pond \u00e0 deux objectifs :
\u2013 des indications cliniques avec de r\u00e9els besoins th\u00e9rapeutiques non satisfaits
\u2013 des cibles tumorales rapidement accessibles, adapt\u00e9es \u00e0 la courte demi-vie de l\u2019astate-211 (7,2h) et dont la petite taille est adapt\u00e9e \u00e0 la tr\u00e8s courte longueur du trajet des particules alpha \u00e9mises.
Notre premier d\u00e9veloppement cible le cancer de la vessie non invasif sur le plan musculaire, r\u00e9fractaire au BCG et \u00e0 la chimioth\u00e9rapie et en attente d\u2019une cystectomie radicale. Le candidat radiopharmaceutique est un anticorps anti-CAIX marqu\u00e9 \u00e0 l\u2019astate-211 \u00e0 l\u2019aide d\u2019une technologie de radiomarquage prot\u00e9g\u00e9e, et d\u00e9velopp\u00e9e \u00e0 Nantes, en France. To know more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Atonco est une soci\u00e9t\u00e9 radiopharmaceutique au stade clinique qui d\u00e9veloppe des produits radiopharmaceutiques innovants utilisant l\u2019astate-211, un radionucl\u00e9ide \u00e9metteur de particules alpha pour le traitement du cancer.<\/p>\n","protected":false},"author":3,"featured_media":22577,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33,36],"tags":[],"class_list":["post-22593","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-new-member","category-news"],"yoast_head":"\nAtonco - new member - MabDesign<\/title>\n<meta name=\"description\" content=\"Atonco est une soci\u00e9t\u00e9 radiopharmaceutique au stade clinique qui d\u00e9veloppe des produits radiopharmaceutiques innovants utilisant l\u2019astate-211, un radionucl\u00e9ide \u00e9metteur de particules alpha pour le traitement du cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atonco - new member - MabDesign\" \/>\n<meta property=\"og:description\" content=\"Atonco est une soci\u00e9t\u00e9 radiopharmaceutique au stade clinique qui d\u00e9veloppe des produits radiopharmaceutiques innovants utilisant l\u2019astate-211, un radionucl\u00e9ide \u00e9metteur de particules alpha pour le traitement du cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-27T09:29:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-27T09:47:14+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/03\/logo-atonco.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"310\" \/>\n\t<meta property=\"og:image:height\" content=\"98\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Laure Delhon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Laure Delhon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/\"},\"author\":{\"name\":\"Laure Delhon\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\"},\"headline\":\"Atonco – new member\",\"datePublished\":\"2024-03-27T09:29:55+00:00\",\"dateModified\":\"2024-03-27T09:47:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/\"},\"wordCount\":191,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/03\/logo-atonco.jpg\",\"articleSection\":[\"New member\",\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/\",\"name\":\"Atonco - new member - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/03\/logo-atonco.jpg\",\"datePublished\":\"2024-03-27T09:29:55+00:00\",\"dateModified\":\"2024-03-27T09:47:14+00:00\",\"description\":\"Atonco est une soci\u00e9t\u00e9 radiopharmaceutique au stade clinique qui d\u00e9veloppe des produits radiopharmaceutiques innovants utilisant l\u2019astate-211, un radionucl\u00e9ide \u00e9metteur de particules alpha pour le traitement du cancer.\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/03\/logo-atonco.jpg\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/03\/logo-atonco.jpg\",\"width\":310,\"height\":98},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atonco – new member\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39\",\"name\":\"Laure Delhon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g\",\"caption\":\"Laure Delhon\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atonco - new member - MabDesign","description":"Atonco est une soci\u00e9t\u00e9 radiopharmaceutique au stade clinique qui d\u00e9veloppe des produits radiopharmaceutiques innovants utilisant l\u2019astate-211, un radionucl\u00e9ide \u00e9metteur de particules alpha pour le traitement du cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/","og_locale":"en_US","og_type":"article","og_title":"Atonco - new member - MabDesign","og_description":"Atonco est une soci\u00e9t\u00e9 radiopharmaceutique au stade clinique qui d\u00e9veloppe des produits radiopharmaceutiques innovants utilisant l\u2019astate-211, un radionucl\u00e9ide \u00e9metteur de particules alpha pour le traitement du cancer.","og_url":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/","og_site_name":"MabDesign","article_published_time":"2024-03-27T09:29:55+00:00","article_modified_time":"2024-03-27T09:47:14+00:00","og_image":[{"width":310,"height":98,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/03\/logo-atonco.jpg","type":"image\/jpeg"}],"author":"Laure Delhon","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Laure Delhon","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/"},"author":{"name":"Laure Delhon","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39"},"headline":"Atonco – new member","datePublished":"2024-03-27T09:29:55+00:00","dateModified":"2024-03-27T09:47:14+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/"},"wordCount":191,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/03\/logo-atonco.jpg","articleSection":["New member","News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/","url":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/","name":"Atonco - new member - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/03\/logo-atonco.jpg","datePublished":"2024-03-27T09:29:55+00:00","dateModified":"2024-03-27T09:47:14+00:00","description":"Atonco est une soci\u00e9t\u00e9 radiopharmaceutique au stade clinique qui d\u00e9veloppe des produits radiopharmaceutiques innovants utilisant l\u2019astate-211, un radionucl\u00e9ide \u00e9metteur de particules alpha pour le traitement du cancer.","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/03\/logo-atonco.jpg","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2024\/03\/logo-atonco.jpg","width":310,"height":98},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/atonco-nouvea-membre\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Atonco – new member"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/e7f929f9c28647aff12061d31ac44f39","name":"Laure Delhon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/066cd19881c24784247d7cba92fef00a9cef88209b15a463ee495ac0fc2ba664?s=96&d=mm&r=g","caption":"Laure Delhon"},"url":"https:\/\/mabdesign.fr\/en\/author\/laure-delhonmabdesign-fr\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/22593","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=22593"}],"version-history":[{"count":1,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/22593\/revisions"}],"predecessor-version":[{"id":22594,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/22593\/revisions\/22594"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/22577"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=22593"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=22593"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=22593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}